title: A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease.
abstract: BACKGROUND
  The prevalence and clinical significance of cytomegalovirus infection is reportedly high in patients with refractory inflammatory bowel disease but is unknown in unselected patients with active disease.
  
  
  METHODS
  In patients admitted for active inflammatory bowel disease, we prospectively studied the presence and significance of cytomegalovirus infection using anti-cytomegalovirus antibodies, cytomegalovirus viraemia and antigenaemia and cytomegalovirus inclusions and cytomegalovirus immunochemistry staining in ileocolonic biopsies.
  
  
  RESULTS
  A total of 64 patients were included (ulcerative colitis, n = 23; Crohn's disease, n = 41), 18 of whom had been on high-dose oral steroids and 11 on immunosuppressants. Anti-cytomegalovirus IgG and IgM were positive in 42 (66%) and 3 (5%) patients respectively. Blood or urine cytomegalovirus replication markers were found in 4 (6%) patients, all of whom had ulcerative colitis. Three patients had cytomegalovirus viraemia and received anti-viral treatment with ganciclovir. Only one of these patients had cytomegalovirus antigenaemia and also associated biopsy-proven cytomegalovirus colitis, probably as a primary cytomegalovirus infection. This patient is the only one who benefitted from anti-viral therapy.
  
  
  CONCLUSIONS
  Cytomegalovirus infection is infrequent in in-patients with active inflammatory bowel disease. Systematic search of cytomegalovirus replication markers should not be performed. Isolated viraemia without associated antigenaemia or direct demonstration of cytomegalovirus in ileocolonic biopsies does not warrant anti-viral therapy.
authors.affiliation: Division de gastroentérologie et d'hépatologie, Hôpital Cantonal Universitaire, Genève, Suisse.
authors.forename: P
authors.initials: P
authors.lastname: de Saussure
authors.forename: A
authors.initials: A
authors.lastname: Lavergne-Slove
authors.forename: M-C
authors.initials: MC
authors.lastname: Mazeron
authors.forename: S
authors.initials: S
authors.lastname: Alain
authors.forename: C
authors.initials: C
authors.lastname: Matuchansky
authors.forename: Y
authors.initials: Y
authors.lastname: Bouhnik
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000032:analysis; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification; D003586:Cytomegalovirus Infections; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D000914:Antibodies, Viral; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007075:Immunoglobulin M